RCUS as reported
Arcus Biosciences, Inc. reported $117M of revenue over the trailing twelve months, −55% on the year before. 10 reported series are charted on this page, each one as filed.
$117M
Revenue, trailing twelve months · to Q2 2026 · −55% against the twelve months before
- Net Income
- −$460M
Net Income · +54% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$475M
Free Cash Flow · +39% year on year · trailing twelve months to Q2 2026
- Op Margin
- −478%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $117M | −55% | Q2 2026 |
| Net Income | −$460M | +54% | Q2 2026 |
| EPS | −$3.91 | +23% | Q2 2026 |
| Op Margin | −478% | n/a | Q2 2026 |
| Net Margin | −454% | n/a | Q2 2026 |
| ROE | −76% | n/a | Q2 2026 |
| ROA | −38% | n/a | Q2 2026 |
| ROIC | 165% | n/a | Q2 2026 |
| Free Cash Flow | −$475M | +39% | Q2 2026 |
| P/E | 35.6 | n/a | Q3 2022 · 15 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Arcus Biosciences, Inc. (RCUS) - Revenue & ProfitRevenue & ProfitArcus Biosciences, Inc. (RCUS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com